文献速递妇科

癌相关成纤维细胞来源的FMO2作为上皮性卵巢癌巨噬细胞浸润与预后生物标志物

Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-09-14

本研究从上皮性卵巢癌样本分离原代成纤维细胞,利用微切割与单细胞RNA测序数据集确定表达谱,发现FMO2在肿瘤间质中上调并与成纤维细胞活化相关,可预测较差临床结局;FMO2与CD163+细胞浸润水平联合可预测不良总生存(HR=3.63,95%CI=1.93-6.84,p=0.0008),并在独立队列(n=113)中验证。

要点

  • FMO2在肿瘤间质中上调,与成纤维细胞活化相关,可预测上皮性卵巢癌较差临床结局。
  • FMO2与CD163+细胞浸润水平联合可预测不良总生存(HR=3.63,95%CI=1.93-6.84,p=0.0008)。
  • FMO2还基于免疫检查点(如PD-L1和PD1)表达预测卵巢癌患者预后。

核心结论

  • FMO2在上皮性卵巢癌中具有肿瘤支持作用并与免疫成分相关,可能成为间质导向治疗的候选靶点。

研究设计与样本

  • 从上皮性卵巢癌样本分离原代成纤维细胞,检索微切割与单细胞RNA测序数据集(包括TCGA、GSE9891、GSE63885、GSE118828和GSE178913)确定表达谱,并在独立上皮性卵巢癌队列(n=113)中验证FMO2与联合巨噬细胞浸润水平的预测价值。

主要发现

  • FMO2在肿瘤间质中上调并与成纤维细胞活化相关。
  • FMO2对上皮性卵巢癌患者较差的临床结局具有预测能力。
  • 在上皮性卵巢癌间质亚型中,FMO2定义的标签显示FMO2促进肿瘤浸润淋巴细胞的浸润。
  • 上皮性卵巢癌组织中FMO2与CD163+细胞浸润水平呈正相关。
  • 肿瘤间质中FMO2表达与CD163+细胞浸润水平联合可预测不良总生存(HR=3.63,95%CI=1.93-6.84,p=0.0008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent molecular profiling revealed that cancer-associated fibroblasts (CAFs) are essential for matrix remodeling and tumor progression. Our study aimed to investigate the role of flavin-containing monooxygenase 2 (FMO2) in epithelial ovarian cancer (EOC) as a novel CAF-derived prognostic biomarker. METHODS: Primary fibroblasts were isolated from EOC samples. Microdissection and single-cell RNA sequencing (scRNA-seq) datasets (including TCGA, GSE9891, GSE63885, GSE118828 and GSE178913) were retrieved to determine the expression profiles. Gene set enrichment analysis (GSEA) was used to explore the correlation between FMO2 and stromal activation as well as immune infiltration. The predictive value of FMO2 and combined macrophage infiltration level was verified in an independent EOC cohort (n = 113). RESULTS: We demonstrated that FMO2 was upregulated in tumor stroma and correlated with fibroblast activation. Besides, FMO2 had the predictive power for worse clinical outcome of EOC patients. In the mesenchymal subtype of EOC, the FMO2-defined signature revealed that FMO2 contributed to infiltration of tumor-infiltrating lymphocytes. Moreover, we confirmed the positive correlation between FMO2 and CD163+ cell infiltration level in EOC tissues, and showed that combination of FMO2 expression with CD163+ cell infiltration level in the tumor stroma could predict poor overall survival (HR = 3.63, 95% CI = 1.93-6.84, p = 0.0008). Additionally, FMO2 also predicted the prognosis of patients with ovarian cancer based on the expression of immune checkpoints (such as PD-L1 and PD1). CONCLUSION: Our results address the tumor-supporting role of FMO2 in EOC and its association with immune components, and it might be a prospective target for stroma-oriented therapies against EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yu S, Yang R, Xu T, et al. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 36114029. doi:10.1016/j.ygyno.2022.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。